Sun03242019

Robins Global News & Noticias



  • Featured Guest Post
    Featured Guest Post
  • Featured Guest Post
    Featured Guest Post
  • Featured Guest Post
    Featured Guest Post
  • Featured Guest Post
    Featured Guest Post
  • Trump Pence News
    Trump Pence News
  • Weather Alerts
    Weather Alerts

RobinsPost News Network

+ Larger Font | + Smaller Font

Consumer Daily Reports

Consumer News: FDA approves new generic version of valsartan

PhotoThe Food and Drug Administration (FDA) has approved a new generic version of the blood pressure drug valsartan, which is also sold under the trade name Diovan. Valsartan is a widely used angiotensin II receptor blocker (ARB) that doctors prescribe for high blood pressure and heart failure.

The approval was placed on the FDA fast track after the agency confirmed the presence of an impurity in several lots of the medicine last year. Researchers detected a trace amount of an unexpected impurity -- N-nitrosodimethylamine (NDMA). NDMA has been classified as a probable human carcinogen by the International Agency for Research on Cancer (IARC).

The discovery led to major recalls of existing forms of valsartan, which in turn led to shortages of the drug.

“To address the public health consequences of these shortages, we've prioritized the review of generic applications for these valsartan products,” said FDA Commissioner Scott Gottlieb. “When faced with a drug shortage situation, the FDA employs a number of strategies to help mitigate the effects of the shortage on patients. As part of that work, we look at where we may be able to prioritize review of pending generic applications of the medicine in shortage, or similar products.”

Gottlieb said he is hopeful the approval of the new generic will quickly alleviate the valsartan shortage. Meanwhile, he says the FDA will step up its efforts to keep impurities out of approved prescription drugs.

Suspected human carcinogen

Valsartan began disappearing from pharmacies in the middle of last year after a Chinese company reported the presence of NDEA in several batches of its valsartan API. It was of special concern since NDEA is a suspected human carcinogen.

The FDA began its tests after the Chinese report and resulting recalls. The FDA probe, completed in September, not only found the impurity in the Chinese company's product, but also in Torrent Pharmaceutical’s valsartan 160mg (lot BV47D001) and 320mg (lots BV48D001 and BV48D002) tablets.

The discovery of a potential carcinogen in a prescription drug may well have been a wakeup call for the agency, It says it has conducted a major investigation to address the presence of nitrosamine impurities in certain generic ARB products.

The FDA says it has also worked with companies to move quickly to remove any products with unacceptable impurities from the U.S. market.



Posted: 2019-03-13 14:41:41

Get Full News Story On Consumer Affairs


Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.






Print Friendly and PDF Share Embed


Related News Stories From The Web And More

Related Bing News

Consumer News: FDA approves new generic version of valsartan | Consumer Daily Reports | RobinsPost News Network - Newscast

FDA approves new generic version of oft-recalled blood pressure and heart medication

Fri, 15 Mar 2019 03:30:00 GMT

The FDA approved a new generic version of valsartan, a blood pressure and heart medication drained into shortage by numerous recalls since July. Alkem Laboratories received the approval. Many lots of ...

FDA approves valsartan generic amid probe into impurities

Thu, 14 Mar 2019 09:42:00 GMT

The Food and Drug Administration approved Tuesday a generic version of the commonly-used high blood pressure medication valsartan, amid a global shortage and probe into impurities of the drug. The FDA ...

FDA approves new generic version of valsartan

Thu, 14 Mar 2019 07:08:00 GMT

The Food and Drug Administration (FDA) has approved a new generic version of the blood pressure drug valsartan, which is also sold under the trade name Diovan. Valsartan is a widely used angiotensin ...

FDA approves generic blood pressure drug over shortages caused by numerous recalls

Wed, 13 Mar 2019 13:51:00 GMT

Read more trending news To ... ship them to generic drug companies throughout the world. Numerous recalls since July have caused a shortage of losartan, valsartan and irbesartan, prompting the FDA to ...

FDA Approves New Valsartan Product Following Major Recall

Wed, 13 Mar 2019 10:38:00 GMT

Alkem Laboratories Limited was granted approval of a new valsartan product free of NDMA and NDEA The Food and Drug Administration (FDA) has approved a new generic version of Diovan (Novartis) that ...

Related Bing Web Search

Generic Diovan Availability - Drugs.com

(Wed, 20 Mar 2019 23:45:00 GMT)

Generic drug availability, manufacturer information, and patent status on Diovan

FDA Approves Generic Proair HFA for Asthma - GoodRx

(Thu, 21 Mar 2019 00:57:00 GMT)

Good news! Another generic albuterol inhaler has just hit pharmacies. Manufacturer Teva just released their generic version of Proair HFA, used to treat asthma.

Valsartan Uses, Side Effects & Warnings - Drugs.com

(Wed, 20 Mar 2019 19:49:00 GMT)

Valsartan is used to treat high blood pressure (hypertension) in adults and children who are at least 6 years old. Valsartan is sometimes given together with other blood pressure medications. Valsartan is also used in adults to treat heart failure, and to lower the risk of death after a heart attack.. Valsartan may also be used for purposes not listed in this medication guide.

Diovan Prices, Coupons & Savings Tips - GoodRx

(Wed, 20 Mar 2019 13:51:00 GMT)

Valsartan (Diovan) is a moderately priced drug used to treat high blood pressure.This drug is also used to treat patients with heart failure and patients who have had a heart attack.This drug is more popular than comparable drugs. It is available in brand and generic versions.

We manufacture niche and complex Pharma ... - Natco Pharma

(Wed, 20 Mar 2019 17:47:00 GMT)

We manufacture niche and complex Pharma products under the pressure of expectation

MYL Stock Quote - Mylan N.V. Ordinary Shares Price - Nasdaq

(Wed, 20 Mar 2019 07:17:00 GMT)

Stock quote for Mylan N.V. Ordinary Shares Common Stock (MYL) with real-time last sale and extended hours stock prices, company news, charts, and research at Nasdaq.

Health & Fitness | Miami Herald

(Thu, 21 Mar 2019 03:05:00 GMT)

Health & Fitness news, advice, and opinions from The Miami Herald newspaper in South Florida.

Latest News - Consumer News

(Thu, 21 Mar 2019 02:22:00 GMT)

ConsumerAffairs News: Go to ConsumerAffairs.com for coverage on the latest consumer news, product recalls and more.

Mylan N.V. Ordinary Shares (MYL) Real-Time Stock Quote ...

(Tue, 19 Mar 2019 07:04:00 GMT)

Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.

Dangerous Drugs & Biologics: Side Effects & FDA Regulation

(Fri, 03 Jan 2014 00:01:00 GMT)

A brand name drug is a drug sold under a proprietary, trademark-protected name. In the case of a brand name drug, a pharmaceutical company discovers a new drug and files for a patent to prevent other companies from copying the drug and selling it.

Related News Story Videos From Youtube

Valsartan Recalled For Cancer Causing Chemical Contamination. Lawsuits to Follow


Related Videos On: Valsartan Recalled For Cancer Causing Chemical Contamination. Lawsuits to Follow


【天下新聞】美國: FDA批准降血壓藥Valsartan學名藥推出 Sky Link TV Chinese News 03132019


Related Videos On: 【天下新聞】美國: FDA批准降血壓藥Valsartan學名藥推出 Sky Link TV Chinese News 03132019


FDA expands recall of Valsartan drugs


Related Videos On: FDA expands recall of Valsartan drugs


Mylan expands nationwide recall for blood pressure medication


Related Videos On: Mylan expands nationwide recall for blood pressure medication


(2018) December. Blood Pressure Medication Recall In The U.S. - NoSaltBP.com


Related Videos On: (2018) December. Blood Pressure Medication Recall In The U.S. - NoSaltBP.com






Blow Us A Whistle

Comments (Whistles) Designed By Disqus




Company Information

Official Content Providers











PRIVACY POLICY

We recommend Firefox 3 (and above), Edge, and Chrome for dynamic performance.
© 2008-2019 RobinsPost (The Bird's Eye View Company) All rights are reserved.
RobinsPost provides links to news sites based on their RSS feeds.
All trademarks, copyrights, videos, photos and logos are owned by news sources.
News stories, videos and live streams are from trusted sources.
ROBINSPOST Is Proudly Made In America.
Where Quality, Safety and Service Comes First.